08/02/2026
Retatrutide is generating a lot of excitement—but it is not currently available for routine patient treatment.
Retatrutide is a once-weekly “triple agonist” targeting three receptors:
🍽️ GLP-1 for appetite control, fullness, and reduced food intake
⚙️ GIP for insulin response, glucose control, and metabolic regulation
🔥 Glucagon for energy expenditure and fat metabolism
Semaglutide targets GLP-1, while tirzepatide targets both GLP-1 and GIP. Retatrutide adds the glucagon receptor, which means it may both reduce calorie intake and influence how the body uses and burns energy. This triple action is why it is gaining so much attention.
Eli Lilly plans to submit retatrutide through a Biologics License Application, or BLA, in early 2027.
Why does this matter?
Biologics are regulated through a separate federal pathway and are not eligible for the usual 503A or 503B compounding exemptions. A compounding pharmacy cannot legally purchase bulk retatrutide and prepare it for patient use.
Today, there is no legal pharmacy source of retatrutide for routine treatment. Anything currently sold online as “retatrutide,” “Reta,” or “research use only” is not FDA approved or legally compounded for human use. Its identity, strength, sterility, and quality may not be verified.
The planned BLA also raises questions about how other peptides may be classified and whether this could limit future pharmacy compounding and patient access.
We will be watching this closely while continuing to prioritize legal sourcing, quality, and patient safety.